

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 25, 2002, 05:12:45 : Search time 203.5 Seconds
(without alignments)
9044.385 Million cell updates/sec

Title: US-09-811-118-2

Perfect score: 1072

Sequence: 1 GAGCCGCCACACTCCGAC.....TTGCATCCAAATGATTTTC 1072

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues 3472872

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N.Geneseq_032802:*

1: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/hold-geneseq/geneseqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1072	100.0	1072	22	AAH46980
2	1068.4	99.7	1321	21	AAC98225
3	1067.2	99.6	1205	22	AAI59813
4	1067.2	99.6	1228	22	AAH14527
5	1067.2	99.6	1511	22	AAH72778
6	1065.6	99.4	1315	22	AAE81788
7	1064.2	99.3	1227	21	AAZ65013
8	1064.2	99.3	1227	22	AA546137
9	1064.2	99.3	1227	22	AA44159

10	1063.2	99.2	1100	22	AAI58027	Human polynucleoti
11	846.8	79.0	872	22	AAH06810	Human CDNA clone (
12	406.2	37.9	751	22	AAH71016	Human cervical can
13	360.2	33.6	528	22	AAH11842	Human CDNA clone (
14	356	33.2	468	22	AAH72087	Human cervical can
15	169.8	15.8	1342	22	AAA96342	CDNA encoding a no
16	169.8	15.8	1342	22	AA546159	Human DNA encoding
17	169.8	15.8	1345	22	AA160677	Human polynucleoti
18	169.8	15.8	1349	21	AAA78428	Human secreted pro
19	169.8	15.8	1417	22	AAI58891	Human polynucleoti
20	158.8	14.8	1362	21	AAH78396	Human secreted pro
21	157.6	14.7	1916	22	AAI26635	Human breast cancer
22	155.4	14.5	514	21	AAA44042	Human secreted exp
23	113.4	10.6	386	21	AAC07552	Human 5' EST isola
24	110.2	10.3	472	21	AAZ42970	Human 5' EST isola
25	91.8	8.6	515	21	AAI41358	Zea mays DNA fragm
26	91.6	8.5	720	14	AAQ05372	Sequence encoding
27	91	8.5	773	21	AAE08001	Fusarium venenatum
28	84.4	7.9	552	21	AAZ38987	Escherichia coli b
29	84	7.8	904	21	AAC40053	Arabidopsis thalia
30	82.6	7.7	498	22	AAC85887	MST-37g1 CDNA. My
31	82.6	7.7	2500	22	AAC85886	Arabidopsis thalia
32	82.4	7.7	889	21	AAC38471	Arabidopsis thalia
33	81.8	7.6	829	21	AAC39100	Arabidopsis thalia
34	81.8	7.6	899	21	AAC47317	Arabidopsis thalia
35	80.2	7.5	441	21	AAC69759	Human breast tumor
36	80.2	7.5	917	21	AAC77635	Human cancer assoc
37	79	7.4	903	21	AAC37412	Arabidopsis thalia
38	78	7.3	832	9	AAH80914	Sequence encoding
39	78	7.3	832	16	AAQ80053	Glutathione peroxi
40	78	7.3	832	17	AAI12329	Human glutathione
41	78	7.3	832	18	AAI43251	Human glutathione
42	77	7.2	761	17	AAI37365	Rat phospholipid h
43	76.4	7.1	545	21	AAC98372	Human colon cancer
44	76.4	7.1	928	20	AA241381	Human normal uteru
45	76.4	7.1	1134	9	AAH80988	Human glutathionin

ALIGNMENTS

RESULT 1
AAH46980
ID AAH46980 standard; cDNA; 1072 BP.

AC AAH46980;

DT 29-OCT-2001 (first entry)

DE Human glutathione peroxidase (GPx6) encoding cDNA.

KW Glutathione peroxidase; GPx6; anti-human immunodeficiency virus; HIV;
KW anti-inflammatory; antiallergic; antidiabetic; antidiabetic; nephrotropic;
KW antineoplastic; antihypertensive; immunosuppressive; antidiabetic; nephrotropic;
KW antiproliferative; osteoplastic; antineoplastic; antineoplastic; antineoplastic;
KW antiproliferative; osteoplastic; antineoplastic; antineoplastic; antineoplastic;
KW antiproliferative; osteoplastic; antineoplastic; antineoplastic; antineoplastic;

OS Homo sapiens.

FN Key Location/Qualifiers
FT CDS 26..589
FT /tag= a
FT /product= "GPx6"

PN US6231853-B1.

PD 15-MAY-2001.

PF 01-JUN-1998; 98US-0088549.

PR 01-JUN-1998; 98US-0088549.

XX

PA (INCY-) INCYTE PHARM INC.

PI Hillman JL, Corley NC, Patterson C;
 PI Hillman JL, Corley NC, Patterson C;
 PI Hillman JL, Corley NC, Patterson C;

DR WPI; 2001-335067/35.

DR P-PSDB; AAB85575.

PT New substantially purified human glutathione peroxidase polypeptide,
PT useful for diagnosing, treating or preventing reproductive disorders,
PT immune disorders and cell proliferative or developmental disorders -

PS Example 1; Fig 1A-C; 26pp; English.

CC This cDNA encodes a human glutathione peroxidase (GPx6) polypeptide. The
CC GPx6 polypeptide is useful for diagnosing, treating or preventing
CC disorders associated with expression of GPx6, where the disorders are
CC selected from reproductive disorders, immune disorders such as acquired
CC immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory
CC distress syndrome, allergies, asthma, atherosclerosis, anemia, autoimmune
CC thyroiditis, bronchitis, diabetes mellitus, glomerulonephritis,
CC Goodpasture's syndrome, gout, multiple sclerosis, myasthenia gravis,
CC osteoporosis, rheumatoid arthritis, cancer, infections and trauma, and
CC cell proliferative or development disorders such as arteriosclerosis,
CC cirrhosis, psoriasis, cancer, Cushing's syndrome, and Sydenham's chorea.
CC GPx6 is also useful to produce antibodies, and to screen libraries of
CC pharmaceutical agents to identify those which specifically binds GPx6.

SQ Sequence 1072 BP; 275 A; 294 C; 270 G; 233 T; 0 other;

Query Match	100.0%	Score 1072;	DB 22;	Length 1072;
Post [local] Similarity	100.0%	Post vs 1	100.0%	

Best Local Similarity 100.0%; Pred. NO. 1.3e-281;
Matches 1072; Conservative 0; Mismatches 0;

Matches 1072; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

[illegible]

OY	601	CGTCGTCACCACTCATATCCGGCGACATGTGGGGGGTACCAGTAATGCAACTGCAATATG	660
Db	601	ccctccccaacacccatccgccccaccgctgctggggctcgaccaatgcacaactcaaaatcg	660
OY	661	TGCTTTCAAAGGAGAGACCCACTGACTCTCTCTTCTTACTGTATATGTCATATGTGCCAT	720
Db	661	tgcttcaaaaggagagacccaccgactctctctcttacttacttatgcatctgctccat	720
OY	721	CATCTTGTCGGGGGAAAAATTTAGTATTTTGTATTTTGAATCTTTACGCAACAATAG	780
Db	721	catctctgctggggaaaaaattccagatatttgattatcttgaactctcaagcaacaataag	780
OY	781	GAACCTCGTGGCAATGAGACTCTTTCAGCAGTAAACACACACCGCATAGCAACTCTTGC	840
Db	781	gaactccgctgcacatcgagctctcttgacccagtgaaactcacacgacgataagaaacgctctgc	840
OY	841	CACACAAAATGTGTGGCAATAGACGATATATCAAGCAATATCTCCACCCAAAGGCTTCT	900
Db	841	caacaaaatatgtgtgagcaaatagaatlatatcaagcaataactcccccgaagctctct	900
OY	901	GTAACCTGGGACCAATCATTAACCTCATATAGGGCTGTGTAGGATTTAGATAGGAATACCTG	960
Db	901	gttaaacctgggagcccaatgatatccttcataagcgcgtctgtgaggaattagatgaaataacctg	960
OY	961	TGAAAGTGCCTAGGCACTGCCAGCCAAATAGAGAGCATTCAATGAAACATTTTTTGCATAT	1020
Db	961	tgaagctgccttaggcagctgcacagcaaatagagagcatccaatgaaacatttttgcatac	1020
OY	1021	AAACCAAAAAAATACTGTATCATATTAATAAAGCTTGATCAACATGAATATTC	1072
Db	1021	aaacccaataataactcgttatccaataaaactctgcatcccaacagaaatttc	1072

RESULT 2

ID AAC98225 standard; cDNA; 1321 BP

AAC98225; AC

DT 09-MAR-2001 (first entry)

Human colon cancer antigen nucleotide sequence SEQ ID NO:235.

KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
identifying antibodies; immunohistochemistry

KW immunomodulatory; muscular; gynaecological; gastrointestinal; neoplastic; anti-infective; antibacterial; bone; therapy; wound.

reproductive disorder; gastrointestinal disorder; renal disorder; muscular disorder; immune system disorder; neural disorder; kw

infectious disease; cardiovascular disorder; ss.

CS
XX
XX

[illegible]

XX

XX

XX

XX

XX

DR P-PSDB; AAB53468.

Colon cancer associated gene sequences, referred to as colon cancer

PT disorders such as colon cancer -
xy

XX The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AA38642-AA44213) with neurotrophic,
CC immunosuppressant and cyostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: immune system suppression,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S. disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX Sequence 1205 BP; 324 A; 321 C; 289 G; 271 T; 0 other;

Query Match	99.6%	Score 1067.2;	DB 22;	Length 1205;
Best Local Similarity	99.7%	Pred. No. 3.1e-280;		
Matches 1069;	Conservative	0;	Mismatches 3;	Indels 0;
				Gaps 0;

QY	1	GAGCGCGCCACTCTCCGGAAGAACGCATGATGCGCGGACAGAGTGGGACGCGCGTGGTGT	60
Db	2	gagcgcgccacctcccggaacaaagccaagctgtagcgcgagctgtagcgagcgcgctgagctgc	61
QY	61	CCTGTGGGCTCGGCGCTGCGGCGAGCGAGGACAGGACTTTTACGACTTCAAGCGGCTCAA	120
Db	62	cctgtgggctctgcgcgctcgcgagcgagcgaggaactctacgacttcaagcggtcga	121
QY	121	CATCGGGGGCAAATGTGTGTGCTTGAGAAAGTACCGGGATTCGTTGTCCTGGTGGTGAA	180
Db	122	catcggyggcaaacctggtgtctgtagaaagtlacgcggagctcggtgccttgtagtga	181
QY	181	TGTGCGCAGCAAGTGTGCGGCTTACAGAGACAGCACTTACCGAGCCCTGAGCAGCTGCAAGG	240
Db	182	tgtgcgcaagcgagtgcggtcttcacagaacagcaactacgcgagccctgagagtgtagcg	241
QY	241	AGACTGGGGCCCCCACCACCTTCAACAGTGTGCTTCCCTCGACACAGTTTGGCCAA	300
Db	242	agaccttgggcccccaacccttcaacggtgtctgccttccctctgaacaaagtttgccaac	301
QY	301	GGAGCCTCAAGCAACAGGAGATTGAGAGCTTTCCTGCGCGACCTACAGTGTCTCAT	360
Db	302	ggagcctgaacgaacaaagagatgttagaggttgcgcgcgcgaacctacagtgctcat	361
QY	361	CCCCATGTTTAGCAAGATGTGCATCACCGGTACTGTGTGTCCTTCCCTTCAAATGCT	420
Db	362	ccccatgttttagcaagatgtgcattcaacgcgtagctgtgtccatcttcgcttcaagtaact	421
QY	421	GGCCGAGACTTGTGGAGAGAGACCACCTGGAATTTGTGAAAGTACCTATACCCCA	480
Db	422	ggccgagacttcttggaagagagcccaacttgaacttctgaaagtaacttagtagccca	481
QY	481	TGGAAGGTGTAGGGCTTGGAGACCCAACTGTCTAGGTGAGAGAGGTCACTACAGAT	540
Db	482	tggaaagtgttagagggcttggaaccacaactgtctagtggaagaggttcagacccegat	541
QY	541	CACAGCGCTGTGAGGAAGTCTATCTCATACCGAAGAGACTTATACACGCGCT	600
Db	542	caacagcgctcgtagaagaagctcaactcaatgaaacggaagaacttaaacaccgcgctc	601
QY	601	CTCTCTCAACACTCATCCGCGCCACCTGTGTGGGGGTGACCAATCAAACTCAATG	660
Db	602	ctctctccacacactcatccgcgcccaactgtgtgggctgtagcgaatgcaactcaaatg	661
QY	661	TGCTTCAAAAGGAGAGACCCACTACTCTCTCTTACTCTTATAGCATTGTGCCAT	720
Db	662	tgtcttcaagaggagaaacccaactgtactctcttcaactcttaacatgcaatgtgtccat	721

Qy	721	CACTCTGTGGGGGAAAAATCTAGATTTTGAATTTTGAATCTTACGCAAAATAG	780
Db	722	cattcttgtygggaaaaattcagatcttctgtacttctgtacttgaacttaagcaacaatag	781
Qy	781	GAACTCTGGGCAATGAGAGCTCTTGACCGATACACAGCCGATAGAACTGTTC	840
Db	782	gaactcttgccaatgtagagctcttgaccagtgaaaccacagccgaatgaagactctgc	841
Qy	841	CAACAAAATGTGTGGCAATPAGAGATPACAAGATPACAAGATPACCTCCACCAAGGCTCT	900
Db	842	caacaaaaatgtygycgaatagagatataatcaagcaataatctccaccacaagctctc	901
Qy	901	GTAACCTGGGCAATGATTACCTCATAGGGCTTTGTGAGATTAGATGAATACCTG	960
Db	902	gtaactctgagccaatgattataccctcaatagagctgtgtgagagcttagagatgaataacxg	961
Qy	961	TGAAAGTCCCTCAGGACAGCGCAGCAATPAGGAGCATTCATGAAACATTTTTCGATTT	1020
Db	962	tgaagatgctcctaggcagatgcgcagccaatagagagcatctcaatgaacatcttttgcacat	1021
Qy	1021	AAACCAAAAATAACTTGTATCATATAAAACTTCGATCCACATGAATTC	1072
Db	1022	aaaaaaaaaataactgttatccatataaaactctgacccaacatgaattc	1073

RESULT	4
AAH14527	
ID	AAH14527 standard; cDNA; 1228 BP.
XX	
AC	AAH14527;
XX	
DT	26-JUN-2001 (first entry)
XX	
DE	Human cDNA sequence SEQ ID NO:12070.
XX	
KM	Human; primer: detection; diagnosis; antisense therapy; gene therapy; ss
XX	
OS	Homo sapiens.
XX	
PN	EP1074617-A2.
XX	
PD	07-FEB-2001.
XX	
PF	28-JUL-2000; 2000EP-0116126.
XX	
PR	29-JUL-1999; 99JP-0248036.
PR	27-AUG-1999; 99JP-0300253.
PR	11-JAN-2000; 2000JP-0118776.
PR	02-MAY-2000; 2000JP-0183767.
PR	09-JUN-2000; 2000JP-0241899.
XX	
PA	(HELI-) HELIX RES INST.
XX	
PI	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI	Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX	
DR	WPI; 2001-318749/34.
XX	
PT	Primer sets for synthesizing polynucleotides, particularly the 5602
PT	full-length cDNAs defined in the specification, and for the detection
PT	and/or diagnosis of the abnormality of the proteins encoded by the
PT	full-length cDNAs -
XX	
PS	Claim 8; SEQ ID 12070; 2537pp + CD ROM; English.
XX	
CC	The present invention describes primer sets for synthesizing 5602
CC	full-length cDNAs defined in the specification. Where a primer set
CC	comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC	to the complementary strand of a polynucleotide which comprises one of
CC	the 5602 nucleotide sequences defined in the specification, where the
CC	oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC	of an oligonucleotide comprising a sequence complementary to the
CC	complementary strand of a polynucleotide which comprises a 5'-end

CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.

XX
XX
SO Sequence 1228 BP; 326 A; 330 C; 290 G; 282 T; 0 other;

Query Match 99.6%; Score 1067.2; DB 22; Length 1228;

Best Local Similarity 99.7%; Pred. No. 3.2e-280;

Matches 1069; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
QY 1 GACGCCGCACCTCTCGGAACAGCCATGTGGCGGACGCGGCTGCTGCT 60
DB 15 gacgcgcacactccggaacaaagcatggtgcygcagcgtgctgctgct 74
QY 61 CCTGTGGCTGGCGGCTCGGACGAGAGAGACTTCTAGACTTCAAGCGGTCAA 120
DB 75 cctgtggtgctggtgctgctgctgctgctgctgctgctgctgctgct 134
QY 121 CATCCGGGGCAAACTGTGTCGCTGGAGAACTACCGCGGATCGGTGCTGCTGA 180
DB 135 catccggggcaaacgtgtgctgctgctgctgctgctgctgctgctgctgct 194
QY 181 TGTGGCCACAGAGTGGCGCTTACAGACAGCACTACCGCCTTACAGAGTGCAGG 240
DB 195 tgtggccacagagtggcgcttaccagacactacagccctgctgctgctgctg 254
QY 241 AACCTGTGGCGGCGGCTCGGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 300
DB 255 aacctgtggcgcccgacacttcaagctgctgctgctgctgctgctgctgctg 314
QY 301 GAGCCTGTACAGCAACAGAGATTTGAGAGCTTGGCTGCGCAGCTACAGTCTCAT 360
DB 315 gagcctgtacagcaaacagagatgagagcttggcgcgacactacagtgctcat 374
QY 361 CCCCATGTTTACAGATTTGACAGTACCGGCTGCTGCTGCTGCTGCTGCTGCT 420
DB 375 ccccatgtttacagatgtgacacgctgctgctgctgctgctgctgctgct 434
QY 421 GGCACAGACTTCTGGGAAGAGCCGACCTGGAACCTTGAAGTACTGTAGCCGAGA 480
DB 435 ggcacagacttctgggaagagcccgacacttgaagacttgaagacttgaagac 494
QY 481 TGGAAAGTGTGAGGGGCTTGGAGCCAACTGTGTCAGTGGAGAGTGCAGACTCCAG 540
DB 495 tggaaagtgtgaggggcttggagccaaactgtgtcagtggagagtgtagaccac 554
QY 541 CACAGGCTGTGAGAGAACCTCATCTACTGAAGCGAAGAGCTTTAACCACCGGCTCT 600
DB 555 cacaggctgtgagagaaactcatctactgaagcgaagaactttaaccacacgctct 614
QY 601 CCGTCTCAGCAGCTCATCCGCGCAGCTGTGTGGGCTGACCAAGCAAACTCAATAG 660
DB 615 cctctcagcagctcatccgcgcacactgtgtgggctgacccaatgcaactcaatg 674
QY 661 TGGTTCAAAGGAGAGACCCACTGACTGCTCTTCTTACTCTTANAGCATTTGGTCCAT 720
DB 675 tggttcaaaggagagaccacactgactctcttactcttaactctgacatgtgccat 734
QY 721 CATTCTGTGGGGGAAATTTCTAGATTTTGAATTTTGAATTTTACAGCAAAATAG 780
DB 735 catctctgtgggggaaatctctagatatttgatatttgatatttgatatttgat 794
```

```
QY 781 GAATCTCTGGCAATGAGAGCTTTGACAGTGAATCACCAGCCGATACGAAGCTCTGC 840
DB 795 gaactctctggcaatgagagcttttaccagtgaaatcaccagcgcgtaagaagcttgc 854
QY 841 CAACAAAAATGTGTGGCAATAGAGATATATCAAGCAATATATCTCCACCAGGCTCT 900
DB 855 caacaaaaatgtgtggcaatagagatataatcaagaataatctccaccagaagcttct 914
QY 901 GTTAACTGGGACCAATGATTACTCTATAGGCGTGTGTGAGATTGAGATGAATACCTG 960
DB 915 gtaaaactgggaccaaatactatcctcaatagagcgtgtgtgagattagatgaatacctg 974
QY 961 TGAAGTCCCTAGGACGATGCGCAGCAAAATAGAGAGGCAATCAATGAATTTTGCATAT 1020
DB 975 tgaagtccctaggaagcgtgtgccaagaataatagagacatcaatgaacatlttgcatal 1034
QY 1021 AAACCAAAAAATTAATGTTTATCAATAAAACTTGATCCACATGAATTTTC 1072
DB 1035 aaaccaaaaaataatgattatcaataaataactgcatccaacatgatttc 1086
```

RESULT 5

AAH72778

AAH72778 standard; cDNA; 1511 BP.

AAH72778;

19-SEP-2001 (first entry)

Human cervical cancer marker nucleic acid 4052.

Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.

Homo sapiens.

WO200142467-A2.

14-JUN-2001.

08-DEC-2000; 2000MO-US33312.

08-DEC-1999; 99US-0169681.

21-DEC-1999; 99US-0171350.

14-MAR-2000; 2000US-0189315.

12-MAY-2000; 2000US-0203791.

09-JUN-2000; 2000US-0210600.

21-JUL-2000; 2000US-0220114.

(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

Schlegel R, Deeds J, Berger A, Zhao X;

WPI; 2001-375006/39.

New isolated nucleic acid for diagnosing and treating cervical cancer

and for assessing and detecting compounds for treating the cancer -

Claim 1, page 845-847; 1051pp; English.

The invention relates to novel genes (AAH68727-AAH73383) associated with
CC cervical cancer with cytostatic activity. The nucleic acids and encoded
CC polypeptides are useful: to assess if a patient is afflicted with
CC cervical cancer or has a pre-malignant condition; to monitor the
CC progression of cervical cancer or a premalignant condition in a patient;
CC and to select and/or assess the efficacy of a compound or therapy for
CC inhibiting cervical cancer in a patient. The nucleic acids may also be
CC useful for gene therapy.

Sequence 1511 BP; 392 A; 421 C; 378 G; 314 T; 6 other;

Query Match 99.6%; Score 1067.2; DB 22; Length 1511;

Matches 1068; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
QY 1 GAGCGCCGACCTCGGAAACGATGGTGGGAGCGAGCGGCGGCTGCT 60
Db 10 gacgcgcgcaccccccgaagaagcaltgvcg9gc9gc9gc9gc9gc9gc 69
QY 61 CCTGTGGGCTGCGGCTTGGCGGAGAGAGAGAGAGAGAGAGAGAGAGAG 120
Db 70 cctgtggtcgtcgccctcgccgagagagagagagagagagagagagag 129
QY 121 CATCCGGGGCAAACTGTGTGCTGAGAGAGTACCGGAGTCCGTGCTGTA 180
Db 130 catccg9gg9caaaactgtgtcgtg9agaagltaccg9gltcgtccctg9 189
QY 181 TGTGGCAGAGAGTGGGGCTTACAGACGACTACCGGCTGAGAGAGTGA 240
Db 190 tgtg9ccagc9agltgc9gtctca9agccagcc9g9cc9g9agc9gc9g 249
QY 241 AGACTGGGGCCCGACACTTCAAGCTGTGCTTCCCTGACAGCAGTTTGG 300
Db 250 .agaccctgg9cccccacacttcaacgtgtcgtccctccctgcaaccag 309
QY 301 GGAGCCTGACAGCAAAAGAGATTGAGAGCTTGGCTGGCGAGCTACAGT 360
Db 310 g9agcctg9aagcaaaag9agaltg9ag9cttgc9gc9gc9gc9gc9gc 369
QY 361 CCCCATGTTTAGCAAGATTGCACTACCGGTACTGGTGGCCATCTGCTTCA 420
Db 370 ccccatglttagaagaatgtc9agltac9gttgc9gttgc9gttgc9gtt 429
QY 421 GGCCAGACTTCTGGAGAGAGCCGACCTGGAATCTTGAGAGTACTAGTACC 480
Db 430 g9cc9agactctg9gaag9ag9cc9cc9g9aactcttgc9ga9gtc9g 489
QY 481 TGGAAAGTGTGTGGGGCTTGGAGCCCACTGTGCTAGTGTAGAGAGTCA 540
Db 490 tgg9aa9gtgtg9g9gttgc9g9cc9aactgtgtc9agltg9a9g9gtc 549
QY 541 CACAGGCTGTGTGAGAGAGTCTCTTACTAGAGCAGAGAGATTATTAAC 600
Db 550 cacag9cctcgtg9ag9ag9ctc9ctc9g9ag9g9ag9ag9ag9ag9ag 609
QY 601 CCTCTTCACACACCTTATCCCGCCACCTGTGTGGGGCTGACCAATGCA 660
Db 610 cctcctcc9cc9cc9cc9cc9cc9cc9cc9cc9cc9cc9cc9cc9cc9 669
QY 661 TGTCTTAAGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 720
Db 670 t9gtctaa9g9g9ag9ag9cc9cc9g9ag9ag9ag9ag9ag9ag9ag 729
QY 721 CATTTCTTGGGGGAAATTTCTAGTATTGATTTGATTTGATTTGATTTG 780
Db 730 catctctgtg9g9g9aa9aatctc9ag9atctt9gtatctt9ga9ctc 789
QY 781 GAACTCTTGGCCATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 840
Db 790 gaactc9ctg9cc9aatg9ag9c9cttgc9ag9gt9atc9cc9g9ag 849
QY 841 CACCAAAAAGTGTGGCAATATAGAATATATCAAGCAATATATCCACCA 900
Db 850 caac9aa9aatgltgtg9caaat9a9at9at9at9at9at9at9at9at 909
QY 901 GTAACGTGGAGCAATGATTAAGTCTAGAGGCTGTTGTGAGATTTAGAT 960
Db 910 gtaaac9tg9g9ac9caatg9at9at9at9at9at9at9at9at9at9 969
QY 961 TGAAGTGCCTAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020
Db 970 tgaag9tgc9ct9ag9c9gt9c9ag9caaat9ag9g9c9at9caat9 1029
QY 1021 AAACCAAAAATATCTTGTATCATATTAATCTTGCATCAACATGATTT 1072
Db 1030 aaac9ca9aa9aat9at9at9at9at9at9at9at9at9at9at9at 1081
```

```
RESULT 7
AAZ65013
ID AAZ65013 standard; cDNA; 1227 BP.
XX
AC AAZ65013;
XX
DT 05-APR-2000 (first entry)
XX
DE Membrane-bound protein PRO828 encoding cDNA.
XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmaceutical; receptor immunoadhesin; gene mapping; ss.
XX
OS Homo sapiens.
XX
PN WO963088-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US12252.
XX
PR 02-JUN-1998; 98US-0087607.
PR 02-JUN-1998; 98US-0087609.
PR 02-JUN-1998; 98US-0087759.
PR 03-JUN-1998; 98US-0087827.
PR 04-JUN-1998; 98US-0088021.
PR 04-JUN-1998; 98US-0088025.
PR 04-JUN-1998; 98US-0088028.
PR 04-JUN-1998; 98US-0088029.
PR 04-JUN-1998; 98US-0088030.
PR 04-JUN-1998; 98US-0088033.
PR 04-JUN-1998; 98US-0088326.
PR 05-JUN-1998; 98US-0088167.
PR 05-JUN-1998; 98US-0088202.
PR 05-JUN-1998; 98US-0088212.
PR 05-JUN-1998; 98US-0088217.
PR 09-JUN-1998; 98US-0088655.
PR 10-JUN-1998; 98US-0088722.
PR 10-JUN-1998; 98US-0088730.
PR 10-JUN-1998; 98US-0088734.
PR 10-JUN-1998; 98US-0088738.
PR 10-JUN-1998; 98US-0088740.
PR 09-JUN-1998; 98US-0088825.
PR 10-JUN-1998; 98US-0088826.
PR 10-JUN-1998; 98US-0088828.
PR 11-JUN-1998; 98US-0088858.
PR 11-JUN-1998; 98US-0088861.
PR 11-JUN-1998; 98US-0088863.
PR 11-JUN-1998; 98US-0088876.
PR 12-JUN-1998; 98US-0089090.
PR 12-JUN-1998; 98US-0089105.
PR 16-JUN-1998; 98US-0089440.
PR 16-JUN-1998; 98US-0089512.
PR 16-JUN-1998; 98US-0089514.
PR 17-JUN-1998; 98US-0089532.
PR 17-JUN-1998; 98US-0089538.
PR 17-JUN-1998; 98US-0089598.
PR 17-JUN-1998; 98US-0089599.
PR 17-JUN-1998; 98US-0089600.
PR 17-JUN-1998; 98US-0089653.
PR 18-JUN-1998; 98US-0089801.
PR 18-JUN-1998; 98US-0089907.
PR 18-JUN-1998; 98US-0089908.
PR 19-JUN-1998; 98US-0089947.
PR 19-JUN-1998; 98US-0089948.
PR 19-JUN-1998; 98US-0089952.
PR 22-JUN-1998; 98US-0090246.
```



```

PR 22-JUN-1998; 98US-0090252.
PR 22-JUN-1998; 98US-0090254.
PR 23-JUN-1998; 98US-0090349.
PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090441.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090547.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091526.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 07-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091982.
PR 09-JUL-1998; 98US-0092182.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.

```

```

PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.
PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 98US-0115565.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
XX WPI: 2000-072883/06.
XX P-PSDB; AA166677.
XX
XX Membrane-bound proteins and related nucleotide sequences -
XX
XX Claim 2; Fig 119; 822pp; English.
XX
XX The invention provides membrane-bound PRO polypeptides and
XX polynucleotides encoding them. The PRO sequences of the invention were
XX identified based on extracellular domain homology screening. The PRO
XX sequences have homology with proteins including LDL receptors, TIE
XX ligands and various enzymes. The membrane-bound proteins and receptor
XX molecules are useful as pharmaceutical and diagnostic agents. Receptor
XX immunoadhesins, for instance, can be used as therapeutic agents to block
XX receptor-ligand interactions. The membrane-bound proteins can also be
XX employed for screening of potential peptide or small molecule inhibitors
XX of the relevant receptor/ligand interaction. The PRO encoding sequences
XX are useful as hybridization probes, in chromosome and gene mapping and in
XX the generation of antisense RNA and DNA. PRO nucleic acid sequences
XX will also be useful for the preparation of PRO polypeptides, especially
XX by recombinant techniques.
XX
XX Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other:

```

```

Query Match          99.3%; Score 1064.2; DB 21; Length 1227;
Best Local Similarity 99.7%; Pred. No. 2.1e-279;
Matches 1066; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4 GCCGCCACCTCCGAAACAAGCCATGCTGCGGCGAGCGGTGGCGCGCTGCTCTCT 63
DB 12 gccgcacactccggaacaagcatgtgtgcgcgcgcgcgcgcgcgcgcgcgcgcgc 71
QY 64 GTGGGCTGGGCTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 123
DB 72 gtcggtcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 131
QY 124 CCGGGGCAAACTGTGTGCTGCTGAGAGATCCGCGGATGCTGCTGCTGCTGCTGCT 183
DB 132 ccggggcaaacactggtgtgcgtcgtgagaagtlacgcgcgcgcgcgcgcgcgcgcgc 191
QY 184 GCGCAGCGAGTGGCTTACAGACCCAGCCTACCGAGCCCTGCGAGCGCTGACCGG 243
DB 192 ggcacagcagtgctcgcgtcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 251
QY 244 CCTGGGCCCCCAGCTTCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 303
DB 252 cctggggcccccaacttcaacgtgtcgcctccctccgcgcgcgcgcgcgcgcgcgcgcgcgc 311
QY 304 GCCTGACAGCAACAAGGATGAGAGCTTTCCTGCGCGCACTTACAGTGTCTATTGCC 363
DB 312 gctgacagcaacaagagatgagagcttgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 371
QY 364 CATGTTAGCAAGATTGCAAGTCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 423

```



```

DB 372 catgtttagcaaatgtagcagtaaccgtagctgtgcccactcctgaccttaagtaactgagc 431
QY 424 CCAAGACTTTGGGAGAGAGACCCACCTGGAACTTTCTGGAACTAGTACTGACCCAGATAG 483
DB 432 ccagactcttggaaggagccacactggaactcttggaagtaactctgagccccagatgg 491
QY 484 AAAGGTGAGGGGCTTGGGACCAACTGTCTAGTGGAGGAGGTGACAGTCACTCAAGTCA 543
DB 492 aaagtgtgtagggcttgtagcccaactgtgcaatgtagggaggtccagccccagatcac 551
QY 544 AGCGCTGTGAGGAAGCTCATCTACTAGAGCGAGAGACTTATACACCGCTGCTCT 603
DB 552 agcgctgtaggaagctatcctactgagcagagaagctataacacgcgctcct 611
QY 604 CCTCCACCACTTCATCCCGCCCACTGTGTGGGCTGAGACCAATGCAACTCAATATGTG 663
DB 612 cctccacacacccatcccccacactgtgtggtggtgaccaaactgcaaatgtagtc 671
QY 664 TTCAAAGGAGAGACCACTGACTGCTCCTTACTCTTATGACATGCTGCTCCATCAT 723
DB 672 ttcaaaaggagagaccacactgactctcctccttactctttagcattggtccatcat 731
QY 724 TCTTGTGGGGAAAAATTTCTACTATTGTTGATTGAACTTTACAGCAACAATAGGAA 783
DB 732 tctgtggtggaataatctagattattgattatcttgaatcttacgacaataagaa 791
QY 784 CTCCTGCGCAATGAGAGCTCTTGACAGTGAATCACCACCCATAGAGAGCTTTCGCA 843
DB 792 ctctctgccaatgagagctcttgacacagtaalcaccacgcaataagacgtcttgcaa 851
QY 844 CAAAAATGTGTGGCAATAGAGTATATCAAGCAATATCTCCACCAAGGCTTCTGTA 903
DB 852 caaaaatgtgtgccaatagaaatagatatacaagaataatctccacccaagctcttgta 911
QY 904 AACTGGGACCAATGATTACTCTCATAGGCTGTTGTGAGATTAAGATGAATACCTGTGA 963
DB 912 aactgggaccaaagtattactcatagagctgtgtgtagatgagatgaataaccgtgta 971
QY 964 AAGTGGCTAGGAGAGCTGACCAAGCAATAGAGATCATGAACTTTTGGATTAATA 1023
DB 972 aagtgccctagagcagtgccagcaaatagagatgacatcaatcttcttgcatataa 1031
QY 1024 CCAAAAAATACTTGTATCAATTAATAAACTTGATCACAATGAAATTTTC 1072
DB 1032 ccaaaaaataactgttcatcaataaaaacttgatccaacatgaatttc 1080

RESULT 8
AAS46137
ID AAS46137 standard; cDNA; 1227 BP.
XX
XX AAS46137;
XX
XX 18-DEC-2001 (first entry)
XX
XX Human DNA encoding PRO polypeptide sequence #213.
XX
XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep; ss;
XX dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
XX blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
XX adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder;
XX PCR primer.
XX
XX Homo sapiens.
XX
XX WO200168848-A2.
XX
XX 20-SEP-2001.
XX
XX 28-FEB-2001: 2001WO-US06520.
XX
XX 01-MAR-2000: 2000WO-US05601.

```

```

PR 02-MAR-2000: 2000WO-US05841.
PR 03-MAR-2000: 2000US-187202P.
PR 06-MAR-2000: 2000US-186682P.
PR 14-MAR-2000: 2000US-189320P.
PR 14-MAR-2000: 2000US-189328P.
PR 15-MAR-2000: 2000WO-US06884.
PR 21-MAR-2000: 2000US-190828P.
PR 21-MAR-2000: 2000US-191007P.
PR 21-MAR-2000: 2000US-191048P.
PR 21-MAR-2000: 2000US-191314P.
PR 28-MAR-2000: 2000US-192655P.
PR 29-MAR-2000: 2000US-193032P.
PR 29-MAR-2000: 2000US-193033P.
PR 30-MAR-2000: 2000WO-US08439.
PR 04-APR-2000: 2000US-194449P.
PR 04-APR-2000: 2000US-194647P.
PR 11-APR-2000: 2000US-195975P.
PR 11-APR-2000: 2000US-196000P.
PR 11-APR-2000: 2000US-196187P.
PR 11-APR-2000: 2000US-196690P.
PR 18-APR-2000: 2000US-196820P.
PR 18-APR-2000: 2000US-198121P.
PR 18-APR-2000: 2000US-198585P.
PR 25-APR-2000: 2000US-199397P.
PR 25-APR-2000: 2000US-199550P.
PR 25-APR-2000: 2000US-199654P.
PR 03-MAY-2000: 2000US-201516P.
PR 17-MAY-2000: 2000WO-US13705.
PR 22-MAY-2000: 2000WO-US14042.
PR 30-MAY-2000: 2000WO-US14941.
PR 02-JUN-2000: 2000WO-US15264.
PR 05-JUN-2000: 2000US-209832P.
PR 28-JUL-2000: 2000WO-US20710.
PR 22-AUG-2000: 2000US-0644848.
PR 24-AUG-2000: 2000WO-US23328.
PR 08-NOV-2000: 2000WO-US30952.
PR 01-DEC-2000: 2000WO-US32678.
PR 20-DEC-2000: 2000WO-US34956.
XX
XX (GENTH ) GENENTECH INC.
XX
XX Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2001-602746/68.
XX P-PSDB: AAU29236.
XX
XX Novel nucleic acids encoding PRO polypeptides, used to diagnose the
XX presence of tumours, such as prostate and breast tumours, in mammals and
XX to screen for modulators of the compounds -
XX
XX Claim 2: Fig 425; 774pp; English.
XX
XX Sequences AAS45925-AAS46231 represent DNA molecules encoding and PCR
XX primers for PRO polypeptides of the invention. The sequences of the
XX invention can be used to detect the presence of a tumour in a mammal by
XX comparing the level of expression of a PRO polypeptide in a test sample
XX of cells from the animal and a control sample of normal cells, whereby a
XX higher level of expression in the test sample indicates the presence of a
XX tumour in the mammal. Mammals include dogs, cats, cattle, horses, sheep,
XX pigs, goats and rabbits but are preferably human. The polypeptides can be
XX used to stimulate tumour necrosis factor (TNF) alpha release from human
XX blood, when contacted with it. A specific polypeptide can be used to
XX stimulate the proliferation or differentiation of chondrocyte cells. The
XX PRO proteins can be used to determine the presence of tumours and also
XX susceptibility to tumour development, particularly adrenal, lung, colon,
XX breast, prostate, rectal, cervical, or liver tumours, in mammalian
XX subjects. The oligonucleotide probes specific for the PRO nucleic acids
XX can be used for genetic analysis of individuals with genetic disorders.
XX
XX Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other:

```

Query Match 99.3%; Score 1064.2; DB 22; Length 1227;
 Best Local Similarity 99.7%; Pred. No. 2.1e-279;
 Matches 1066; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 4 GCCGCCACCTCCGGAACAGCCATGTGGCGGACGGTGACAGCGGCTGCTCCT 63
   |||||||
DB 12 gccgcacaccccggaacagcatgtgctgcgacgctgcaagcgcgtctccct 71
   |||||||
QY 64 GTGGGGCTGGCGCGGACGAGGAGGAGCTTCTACAGCTTCAAGGCGGTCACAT 123
   |||||||
DB 72 gtggtctgctgcctgcgcgacgagcaggtctctacgacttcaaggcgttcaacat 131
   |||||||
QY 124 CCGGGGCAAACTGCTGCTGCGAGAGATCACCGGATCGGTGCTCTGTGATGT 183
   |||||||
DB 132 ccggggcaaaactgtgtgcgtggaagtaacgcygactgtccctgtgtgtaatgt 191
   |||||||
QY 184 GGGCAGCAGATGGCGCTTACACAGCAGCAGCTACCGAGCCCTGACAGCAGTGCAGCA 243
   |||||||
DB 192 ggcacagagtgctgcttcacagcagcactacagcagccttcagcagctgcagcaga 251
   |||||||
QY 244 CCTGGGCCCCCACCACCTTCAACGAGCTGCGCTTCCCTGCACCAAGTTTGGCCAAACGAGA 303
   |||||||
DB 252 cctgggccccacacacttcaagctgtcgtctccctgcacacagtttgcacacaga 311
   |||||||
QY 304 GCCTGACAGCAGACAGAGATTTGAGAGCTTGGCTGCGGACCTACAGTGTCTATTC 363
   |||||||
DB 312 gcttgacagcaacaagaagatltgagagcttgcgcgcgacactaagtttccattcc 371
   |||||||
QY 364 CATGTTAGCAAGATGTCATCAGCTACCGGTACTGGTCCCACTGCGCTTCAAGTACCTGCG 423
   |||||||
DB 372 catgtttagaagaatltgcaatcacggtactgtgcacacccgcttcaagtaaccg 431
   |||||||
QY 424 CCAGACTTCTGGAGAGAGAGCCCACTGGAATCTGTGAACTTACCTAGTACCCAGATG 483
   |||||||
DB 432 ccagacttctggaagagagagccacactggaacttcgtgaagtaactgtagccacagatg 491
   |||||||
QY 484 AAAGGTGTGTAGGGGCTTGGAGCCCAACTGTGTAGTGTGAGGAGGTGAGACTCCAGATCAC 543
   |||||||
DB 492 aaaggtgtgtaggggcttggagcccaactgtgtcagtgagaggtcagaccagatcac 551
   |||||||
QY 544 AGGCGTGTGAGAGAGCTGCTTACTGAGCGAGAAAGATTATACCACTGCGTCTCCT 603
   |||||||
DB 552 aggcctgtgagagagctctctactcgaagcgaagaactataaccacgcgtccct 611
   |||||||
QY 604 CCTCACACACCTCATCCCGGCCACCTGTGTGTGGGCTGACCAATGCAAACTCAATGGTGC 663
   |||||||
DB 612 cctcacacacactcatcccgccacactgtgtggtggtgacaaatgcacaaatgtgtgc 671
   |||||||
QY 664 TTCAAAAGGAGAGACCCACTGACTCTCTCTTCTTACTCTTATGCAATTTGCTCCATCAT 723
   |||||||
DB 672 ttcaaaaggagagaccacactgactctcttacttacttacttgcattgttccatcat 731
   |||||||
QY 724 TCTTGTGGGGGAAATTTAGTATTTTGTATTTTGAATCTTACAGCAATATATGGA 783
   |||||||
DB 732 tcttgtgggggaaaaatcttagatatttgatctatctgaaacttaccagcaacaatagga 791
   |||||||
QY 784 CTCCTGCGCAATGAGAGCTTGTGACCAAGTGAATCACAGCGCGATAGAGAGCTTGGCAA 843
   |||||||
DB 792 ctctctgccaatgagagctcttgaccagtgatcaccaagcgatcagaaagcttgcac 851
   |||||||
QY 844 CAAAAATGTGTGGCAATAGAGATATATACAGCAATATATCTCCACCCAAAGGCTTCTGA 903
   |||||||
DB 852 caaaaatgtgtggcaaatagaaatatacaagaataatctccacccaaggtcttcgtga 911
   |||||||
QY 904 AACTGGAGCAATGATTACTCTCATAGGGCTGTGTGAGATTGAGTGAATATCTGTGA 963
   |||||||
DB 912 aactggagcaaatgattactctcatagggcgttgtgaggttagagtaagaaaccgttga 971
   |||||||
QY 964 AAGTGCCTTAGGAGTGCAGCAGCAAAATAGAGAGCATTCATGAAATTTTTCATTA 1023
   |||||||
DB 972 aagtgccttaggagtgctgcagcgaataagagagcatcattcaatgaacatttlttgatataa 1031
   |||||||
QY 1024 CAAAAAATTAATTTGTTATCAATAAAAAATCTTGATCCAAACATGAATTTTC 1072

```

```

DB 1032 ccaaaaataactgttatcaataaaactgcatccacaatgatatttc 1080
   |||||||
RESULT 9
AAFA4159
ID AAFA4159 standard; cDNA; 1227 BP.
XX
AC AAFA4159;
XX
DT 02-APR-2001 (first entry)
XX
DE Human PRO828 (UNQ469) nucleotide sequence SEQ ID NO:188.
XX
KW Human: secreted and transmembrane protein; PRO; cytosolic;
KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW diagnostic assay; ss.
XX
OS Homo sapiens.
XX
PN MO200073454-A1.
XX
PD 07-DEC-2000.
XX
PE 30-MAR-2000; 2000MO-US08439.
XX
PR 02-JUN-1999; 99MO-US12252.
PR 23-JUN-1999; 99US-0141037.
PR 07-JUL-1999; 99US-0143048.
PR 20-JUL-1999; 99US-0144758.
PR 26-JUL-1999; 99US-0145698.
PR 28-JUL-1999; 99US-0146222.
PR 17-AUG-1999; 99US-0149396.
PR 15-SEP-1999; 99MO-US21090.
PR 15-SEP-1999; 99MO-US21547.
PR 08-OCT-1999; 99US-0158663.
PR 30-NOV-1999; 99MO-US28313.
PR 01-DEC-1999; 99MO-US28301.
PR 16-DEC-1999; 99MO-US30095.
PR 20-DEC-1999; 99MO-US30911.
PR 05-JAN-2000; 2000MO-US00219.
PR 06-JAN-2000; 2000MO-US00376.
PR 11-FEB-2000; 2000MO-US03365.
PR 18-FEB-2000; 2000MO-US04341.
PR 22-FEB-2000; 2000MO-US04414.
PR 24-FEB-2000; 2000MO-US04914.
PR 24-FEB-2000; 2000MO-US05004.
PR 02-MAR-2000; 2000MO-US05841.
PR 15-MAR-2000; 2000MO-US06884.
PR 20-MAR-2000; 2000MO-US07377.
XX
PA (GENE ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DJ,
PI Ferrara N, Fong S, Geber H, Gerlitsen ME, Goddard A, Godowski PJ,
PI Grimaldi CJ, Gurey AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WJ,
PI Zhang Z.
XX
DR WPI: 2001-032160/04.
DR P-PSDB: AAB65200.
XX
PT PRO polynucleotides used to produce polypeptides used to target
PT bioactive molecules such as toxins, radiolabels or antibodies, to
PT specific cells, to cause targeted cell death -
XX
PS Claim 2: Fig 119; 935pp; English.
XX

```

The present invention describes human secreted and transmembrane PRO proteins. The PRO proteins have cytostatic activity. The PRO proteins can be used for targeted delivery of bioactive molecules, such as toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide sequences, and their fragments, can be used as hybridisation probes, in

CC chromosomal and gene mapping, and in the generation of anti-sense RNA
 CC and DNA. They may also be used to produce transgenic animals which are
 CC used to develop and screen therapeutically useful reagents. The PRO
 CC nucleotide and protein sequence can be used for tissue typing and in
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
 CC AA44270 to AA44470 represent PCR primers and hybridisation probes used
 CC in the isolation of human PRO sequences. AA44087 to AA44269 and
 CC AA65154 to AA65300 represent human PRO polynucleotide and protein
 CC sequences given in the exemplification of the present invention.
 XX
 S0 Sequence 1227 BP; 331 A; 325 C; 293 G; 278 T; 0 other:

Query Match 99.3%; Score 1064.2; DB 22; Length 1227;
 Best Local Similarity 99.7%; Pred. No. 2.1e-279;
 Matches 1066; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 4 GCCGCCACCTCCGAGAACACCATGTGGCGGACGGTGGCAGCGCGTCTCTCTCT 63
DB 12 gccgcacacctccgacacagcatgtgcygcgacgcygcgacgcygcgtctctct 71
QY 64 GTGGGCTGGGCTGGGCGGACGAGGACTTTACGACTTCAAGGGCGGTCAACAT 123
DB 72 gctggctgcygcgcygcgacgacgagcagactctacgactcaagcygcgtaacat 131
QY 124 CCGGGGCAAACTGTGTGTGTGAGAGATACCGCGATCGGTCTCCGTGTAATGT 183
DB 132 ccggggcaaacgtgtgtgtgagaaagtaacgcygaltccggtgtgtgtgtgtgt 191
QY 184 GGGCAGGAGTGGGCTTTCACAGACGACGACTACCGAGCCCTGACGAGCTGACGAG 243
DB 192 ggcgcagagtgcygcgttcacagacagcagactacgagccctgcagcagctgcag 251
QY 244 CCTGGGCCCCACCACTCAACGTGTGCTTCCCTCCCAACGATTGGCCACAGAGA 303
DB 252 ccggggcccccacacttaacgtgtcctccctccgacacagcttgcacacagga 311
QY 304 GCGTACACAGCAACAGAGATTTGAGAGCTTTGCTGCGCACCTACAGTGTCTATTCCC 363
DB 312 gcttcagacagcaacagagatgagagcttgcgcgcgacactacagtgcttctccc 371
QY 364 CATGTTTACGAAGATTTGACAGTACCGGTACTGTGTGCTTCCCTCAAGTACCTGGC 423
DB 372 catgtttacgaagatgagtaacgagctgtgtccatcctgccttcaagtaacctg 431
QY 424 CCAGACTTCTGGGAGAGGCCCCACTGGAACCTTGAAGTACTGAGTACCTGAGTACCTGGC 483
DB 432 ccagactctcggagagagcccaactggaactctggaagtacctaagtagcccaagat 491
QY 484 AAAGGTGTAGGGGCTTGGAGCCCAACTGTGTCACTGAGAGGTACAGTCAAGATCAC 543
DB 492 aaagtgtaggggcttggagcccaactgtgtcagtgagggaggtccagaccccaatcac 551
QY 544 AGCGCTCTGAGAGAGTCTACTCTACTGAAGCGAGAACTTATAACCAACCGCTCTCT 603
DB 552 agcgctctgagagagctcatctactactgaagcgagaaactataccacccgctctct 611
QY 604 CCTCAGCAGCTCACTCCGCGCCACTGTGTGGGCTGACCATGCAAAATCAAAATGTGC 663
DB 612 cctcagacacccatcccgcccaactgtgtgggctgaccaaatacaatacaatcgtgtc 671
QY 664 TTCAAAGGAGAGACCACTGACTCTCCCTTCTTACTTATGACATTTGACCATCAT 723
DB 672 ttcaaaggagagacccacactctctctctcttactctctatgtccatgtcccatcat 731
QY 734 TCTTGTGGGGAAAAATTTCTAGTATTTTGAATTATTTGAATCTTTACAGCAACAATAGGAA 783
DB 732 tcttgtggggaaaaatctctagatatttgatattgaatcttaacagcaacaataagaa 791
QY 784 CTCCTGGGCAATGAGAGCTTTGACACGATGATCCAGCGGATGAGAGCTTGCCAA 843
DB 792 cctcctggcacaatgagagctcttgaccagtgaaacccagcgcagatcgaagctctgcaa 851

```

```

QY 844 CAAAATGTGTGGCAAAATGAGATATATCAACCAATATCTCCACCCAAAGGCTTCTGTA 903
DB 852 caaaaatgtgtggcaaaatgagatataatcaacaaataatctccacccaagctctgta 911
QY 904 AACTGGGACCAATGATTACTTACGAGGCTGTTGTGAGGATTTAGATGAATACCTGTGA 963
DB 912 aactgggaccaaatagattacttaccatagagctgtgtgagattagatgaataaccgtga 971
QY 964 AAGTGCTGTGGGAGGCGCAGCAAAATGAGAGGATTCATGAACATTTTTCGATTAA 1023
DB 972 aagtgctgtgggagggcgacgcaaaaatgagagatcattcaatgacatcttgcatauaa 1031
QY 1024 CCAAAAATATACCTGTTATCAATTAATAAACTTCATCCAAATGAATTTTC 1072
DB 1032 ccaaaaataacttgttatcaataaaacttgcatccacaatgaaatcttc 1080

```

RESULT 10
 AA158027
 ID AA158027 standard; cDNA; 1100 BP.

AC AA158027;

DT 22-OCT-2001 (first entry)

XX Human polynucleotide SEQ ID NO 230.

KW Human; neotropic; immunosuppressant; cytostatic; gene therapy; cancer;

KW peripheral nervous system; neuropathy; central nervous system; CNS;

KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;

KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;

KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;

KW Leukemia; ss.

OS Homo sapiens.

PN WO200153312-A1.

PD 26-JUL-2001.

XX 26-DEC-2000; 2000MO-US34263.

PF 21-JAN-2000; 2000US-0488725.

PR 25-APR-2000; 2000US-0552317.

PR 09-JUL-2000; 2000US-0598042.

PR 13-JUL-2000; 2000US-0620312.

PR 03-AUG-2000; 2000US-0653450.

PR 14-SEP-2000; 2000US-0662191.

PR 19-OCT-2000; 2000US-0693036.

PR 29-NOV-2000; 2000US-0727344.

XX (HISE-) HISEQ INC.

XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;

PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;

PI Zhao QH, Zhou P, Goodrich R, Drmanac RT;

XX WPI. 2001-442253/47.

DR P-PSDB; AAM38671.

PT Novel nucleic acids and polypeptides, useful for treating disorders

PT such as central nervous system injuries -

PS Claim 1; SEQ ID NO 230; 10078bp; English.

XX The invention relates to human nucleic acids (AA157798-AA161369) and

CC the encoded polypeptides (AAM38642-AA442213) with neotropic,

CC immunosuppressant and cytostatic activity. The polynucleotides are useful

CC in gene therapy. A composition containing a polypeptide or polynucleotide

CC of the invention may be used to treat diseases of the peripheral nervous

CC system, such as peripheral nervous injuries, peripheral neuropathy and

CC localized neuropathies and central nervous system diseases, such as

CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic

lateral sclerosis, and Shy-Drager Syndrome. Other uses include the utilisation of the activities such as: Immune system suppression, Activin/Inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, cancer diagnosis and therapy, drug screening, assays for receptor activity, arthritis and inflammation, leukaemias and C.N.S disorders.

Note: The sequence data for this patent did not form part of the printed specification.

50 Sequence 1100 BP; 288 A; 305 C; 277 G; 230 T; 0 other;

Query Match	99.28;	Score 1063.2;	DB 22;	Length 1100;
Best Local Similarly	99.78;	Pred. No. 3.7e-279;		
Matches 1065; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

QY	1	GACGCGCACCTCCGGAAACAAGCATGGTGGCGCGANCGGTGGCAAGCGCGCTGGTGCT	60
Dp	23	gaagcgcacactccctcggaacaagaatgtagtggcgcgaaaggcgagcggtgctgctgct	82
QY	61	CCTGTGGCCTGCGGCCTCGCGCAGCAGAGAGACTTCATCGATTCAAAGCGGTCAA	120
Dp	83	cctgtggcctgagcgcttcgcgcaagagaggaactcttaagcttaagcggtcca	142
QY	121	CATCCGGGGGCAACTGNGTGTGCTGGAGAATAACCGCGAATGGGTGCCGTGTGA	180
Dp	143	catccgggggcaaacctggtgctcgctggagaagaaccgagatctggtgtcccttggtgtaa	202
QY	181	TGTGGCCAGCAGTAGTCGGCTTCACAGACCAGCAGTACGAGCCCTTCAGACACTCGAGG	240
Dp	203	tgtggccagcgagtgcgcttcaacagacagataccagagccttcgacgctgcaagtcaag	262
QY	241	AGACCTGGGGCCCCCACCACCTTCACGTGCTGCCTCCCTCCTAACACGATTGGCCAACA	300
Dp	263	agacctggcccccccacacttcaagtgctcgctctcccttcgcaacagtttggccaaca	322
QY	301	GGAGCTTCACAGSCAACAGAGAGATTGAAGACTTTGCTCGCGCAGCTCAGTGTCAATT	360
Dp	323	ggagcttcacagcaacaagaagattgtagagctttgccgcgcaactaagtgctcaatc	382
QY	361	CCCCATGTTTAGCAAGATTGCATCCGGTACTGTGTGCCATCCCTTGCCTAAGTACCT	420
Dp	383	ccccatgttttagcaaatlttcagttcacgcgtaactgtgtcccaactcgtccttaagtaact	442
QY	421	GGCCAGACTCTTGGGAAGGAGGCCACCTGGAACTTGGGAAGTACGATAGTCCCACAGA	480
Dp	443	ggccagactcttgggaaggagcccccaacttggaaacttcggaaagtaactcagtagtccccaga	502
QY	481	TGAAAAGGTGTAGGGGCTTGGAACCAACTGTGTCACTGGAGAGAGTCCAGCTCCAGAT	540
Dp	503	tggaaaagtgtaggggtgtggaaaccaactgtgtcagtgtagggaggtcagagccccagat	562
QY	541	CACAGCGTGTGAGGAMGTCATCCTACTGTGAAGGAGAAAGACTTATTAACACCGCGTCT	600
Dp	563	cacagcgctctgggaagcttcaactcactcgaagagaaagacttaacaacacgcgctct	622
QY	601	CCTCTCCACACACTCATCCCGCCACCTGTGTGGGGGTGACCAATGGAAAACTCAAAATGG	660
Dp	623	cctctccacacactcatccgcgccaaactgtgtggggtgcacaaatgcaaaatcaaaagg	682
QY	661	TGCTTCAAGGAGAGACCACTACTCTCCTTACTCTTATGGCATTTGGTCCAT	720
Dp	683	tgtctcaaaaggagagaccactgaactctctctccttaactcttatgcatgtgccat	742
QY	721	CATTCTGTGGGGAAAAATCTAGTATTTTGATTATTTGAACTTACAGACAACAATAG	780
Dp	743	catctctgtggggaaaaatctaglatlctgatatlattgaatcctlaagaacaacaatatag	802
QY	781	GAATCTCTGGCAATGAGAGCTTTGACACATGATATCACAGCGAATCGAAGCGTCTGC	840
Dp	803	gaactccttgccaatgtgagctcttgaaccagtgatataccaagccgagatcgaagtgcttgc	862
QY	841	CAACAAAATGTGTGGCAAAATAGAAGTATATCAAGCAATAATCTCCACCCAGAGCTTCT	900

Db	863	caacaaaaatcgttgycaaatagatataccaagcaataatcccccacaaagcttct	922
Qy	901	GTAACCTGGAGCAACAAATGATTACTCATAGAGGCTTTGTGAGGATTAGAGTAATTACCTG	960
Db	923	gtaaacatggagcaaatatgattactcctcaatagagctcttcttgaggtatgaaatacctg	982
Qy	961	TGAAGTGCCTTAGCAGATGCGACGCAAAATGAGAGCAATTCAAATGACATTTTTCATAT	1020
Db	983	tgaagtgccttagcagctgccaagcaaatggaggtcaatgaacaatttttgcatal	1042
Qy	1021	AAACCAAAAATATACATTGTTTATCAATPAAAACCTTGATCCACATGAA	1068
Db	1043	aaaacaaaaataactctgttataataaaaaactgcatacaacatgaa	1090
RESULT	11		
AAH06810			
ID	AAH06810	standard; cDNA; 872 BP.	
XX			
AC	AAH06810;		
XX			
DT	26-JUN-2001	(first entry)	
XX			
DE	Human cDNA clone (5'-primer) SEQ ID NO:3645.		
XX			
KW	Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.		
OS	Homo sapiens.		
XX			
PN	EP1074617-A2.		
XX			
PD	07-FEB-2001.		
XX			
PF	28-JUL-2000; 2000EP-0116126.		
XX			
PR	29-JUL-1999; 99JP-0248036.		
PR	27-AUG-1999; 99JP-0300253.		
PR	11-JAN-2000; 2000JP-0118776.		
PR	02-MAY-2000; 2000JP-0183767.		
PR	09-JUN-2000; 2000JP-0241899.		
XX			
PA	(HELI-) HELIX RES INST.		
PI	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;		
PI	Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;		
XX			
DR	WPI; 2001-318749/34.		
PT	Primer sets for synthesizing polynucleotides, particularly the 5602		
PT	full-length cDNAs defined in the specification, and for the detection		
PT	and/or diagnosis of the abnormality of the proteins encoded by the		
PT	full-length cDNAs -		
XX			
PS	Claim 1; SEQ ID 3645; 2537pp + CD ROM; English.		
XX			
CC	The present invention describes primer sets for synthesizing 5602		
CC	full-length cDNAs defined in the specification. Where a primer set		
CC	comprises: (a) an oligo-dT primer and an oligonucleotide complementary		
CC	to the complementary strand of a polynucleotide which comprises one of		
CC	the 5602 nucleotide sequences defined in the specification, where the		
CC	oligonucleotide comprises at least 15 nucleotides; or (b) a combination		
CC	of an oligonucleotide comprising a sequence complementary to the		
CC	complementary strand of a polynucleotide which comprises a 5'-end		
CC	sequence and an oligonucleotide comprising a sequence complementary to a		
CC	polynucleotide which comprises a 3'-end sequence, where the		
CC	oligonucleotide comprises at least 15 nucleotides and the combination of		
CC	the 5'-end sequence/3'-end sequence is selected from those defined in		
CC	the specification. The primer sets can be used in antisense therapy and		
CC	in gene therapy. The primers are useful for synthesizing polynucleotides,		
CC	particularly full-length cDNAs. The primers are also useful for the		
CC	detection and/or diagnosis of the abnormality of the proteins encoded by		
CC	the full-length cDNAs. The primers allow obtaining of the full-length		

CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.

SQ Sequence 872 BP; 197 A; 259 C; 233 G; 183 T; 0 other;

Query Match 79.0%; Score 846.8; DB 22; Length 872;
Best Local Similarity 99.2%; Pred. No. 2,6e-220;
Matches 851; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1 GAGCGCGCCACCTCGGAAACACCATGATGCGGCGAGCGGCGCGGCTGCT 60
DB 15 GAGCGCGCGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 74
QY 61 CCGTGGGCG 120
DB 75 CCGTGGGCG 134
QY 121 CATCG 180
DB 135 CATCG 194
QY 181 TGTGGCG 240
DB 195 TGTGGCG 254
QY 241 AGACCTGGGCG 300
DB 255 AGACCTGGGCG 314
QY 301 GAGCG 360
DB 315 GAGCG 374
QY 361 CCCCATGTTTCAAGATGATGATGATGATGATGATGATGATGATGATGATG 420
DB 375 CCCCATGTTTCAAGATGATGATGATGATGATGATGATGATGATGATGATG 434
QY 421 GCG 480
DB 435 GCG 494
QY 481 TGGAAAGGTGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 540
DB 495 TGGAAAGGTGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 554
QY 541 CACAGCG 600
DB 555 CACAGCG 614
QY 601 CCTCTCCACACCTTCATCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 660
DB 615 CCTCTCCACACCTTCATCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 674
QY 661 TGGCTTCAAGGAGAGACCATGATGATGATGATGATGATGATGATGATGAT 720
DB 675 TGGCTTCAAGGAGAGACCATGATGATGATGATGATGATGATGATGATGAT 734
QY 721 CATTTCTTGGGGGAAATTTCTAGATTTTCTAGATTTTCTAGATTTTCTAG 780
DB 735 CATTTCTTGGGGGAAATTTCTAGATTTTCTAGATTTTCTAGATTTTCTAG 794
QY 781 GAATCTCTGGCAATGAGCTCTTGACAGTGAATCACCAGCGATACGATCTTGC 840
DB 795 GAATCTCTGGCAATGAGCTCTTGACAGTGAATCACCAGCGATACGATCTTGC 854
QY 841 CAACAAATATGTGTGCA 858
DB 855 CAACAAATATGTGTGCA 872

RESULT 12
AAH71016/C
ID AAH71016 standard; cDNA; 751 BP.
XX

AAH71016;

19-SEP-2001 (first entry)

Human cervical cancer marker nucleic acid 2290.

Cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.

Homo sapiens.

WO200142467-A2.

14-JUN-2001.

08-DEC-2000; 2000MO-US33312.

08-DEC-1999; 99US-0169681.

21-DEC-1999; 99US-0171350.

14-MAR-2000; 2000US-0189315.

12-MAY-2000; 2000US-0203791.

09-JUN-2000; 2000US-0210600.

21-JUL-2000; 2000US-0220114.

(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

Schlegel R, Deeds J, Berger A, Zhao X;

WPI; 2001-375006/39.

New isolated nucleic acid for diagnosing and treating cervical cancer

and for assessing and detecting compounds for treating the cancer -

Claim 1; Page 484; 1051pp; English.

The invention relates to novel genes (AAH68727-AAH73383) associated with

cervical cancer with cytostatic activity. The nucleic acids and encoded

polypeptides are useful: to assess if a patient is afflicted with

cervical cancer or has a pre-malignant condition; to monitor the

progression of cervical cancer or a premalignant condition in a patient;

and to select and/or assess the efficacy of a compound or therapy for

inhibiting cervical cancer in a patient. The nucleic acids may also be

useful for gene therapy.

Sequence 751 BP; 194 A; 141 C; 143 G; 269 T; 4 other;

Query Match 37.9%; Score 406.2; DB 22; Length 751;

Best Local Similarity 99.1%; Pred. No. 2e-100; Mismatches 3; Indels 1; Gaps 1;

Matches 419; Conservative 0; Mismatches 3; Indels 1; Gaps 1;

QY 650 AACTCAATGAGTCTCAAGGAGAGACCATGATGATGATGATGATGATGATGAT 709

DB 745 AACTCAATGAGTCTCAAGGAGAGACCATGATGATGATGATGATGATGATGAT 687

QY 710 ATTGATCCATCATTTCTTGGGGGAAATTTCTAGATTTTCTAGATTTTCTAG 769

DB 686 ACTGATCCATCATTTCTTGGGGGAAATTTCTAGATTTTCTAGATTTTCTAG 627

QY 770 GCACAAATAGAGAACTCCGCAATGAGCTCTTGACAGTGAATCACCAGCGATAC 829

DB 626 GCACAAATAGAGAACTCCGCAATGAGCTCTTGACAGTGAATCACCAGCGATAC 567

QY 830 GAACGCTTGGCAACCAATATGATGATGATGATGATGATGATGATGATGATGAT 889

DB 566 GAACGCTTGGCAACCAATATGATGATGATGATGATGATGATGATGATGATGAT 507

QY 890 CCAAGGCTTCTGTAACCTGGGACCAATGATTTACCTATGAGGCTGTGTGAGGATTA 949

Db 506 CCAAGGCTTCTGTAACTGGGACCAATGATTACCTCATAGGCTGTGTGAGATTAGGA 447
 Qy 950 TGAATACCTGTGAAGTGCCTTAGCAGTGCAGCCAAATAGAGGCAATCAATGAACAT 1009
 Db 446 TGAATACCTGTGAAGTGCCTTAGCAGTGCAGCCAAATAGAGGCAATCAATGAACAT 387
 Qy 1010 TTTTTCATATTAACCAAAAATACCTGTATCAATTAATAAATCTGCATCCCAATGAAT 1069
 Db 386 TTTTTCATATTAACCAAAAATACCTGTATCAATTAATAAATCTGCATCCCAATGAAT 327
 Qy 1070 TTC 1072
 Db 326 TTC 324
 RESULT 13
 AAH1842/C
 ID AAH1842 standard; cDNA; 528 BP.
 AC AAH1842;
 XX 26-JUN-2001 (first entry)
 DE Human cDNA clone (3'-primer) SEQ ID NO:8677.
 XX Human; primer: detection; diagnosis; antisense therapy; gene therapy; ss.
 OS Homo sapiens.
 XX EP1074617-A2.
 PN 07-FEB-2001.
 PD 28-JUL-2000; 2000EP-0116126.
 PF 29-JUL-1999; 99JP-0248036.
 PR 27-AUG-1999; 99JP-0300253.
 PR 11-JAN-2000; 2000JP-0118776.
 PR 02-MAY-2000; 2000JP-0183767.
 PR 09-JUN-2000; 2000JP-0241899.
 XX (HELI-) HELIX RES INST.
 PA Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
 PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
 DR WPI; 2001-318749/34.
 XX Primer sets for synthesizing polynucleotides, particularly the 5602
 PT full-length cDNAs defined in the specification, and for the detection
 PT and/or diagnosis of the abnormality of the proteins encoded by the
 PT full-length cDNAs -
 PS Claim 3; SEQ ID 8677; 2537pp + CD ROM; English.
 CC The present invention describes primer sets for synthesizing 5602
 CC full-length cDNAs defined in the specification. Where a primer set
 CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
 CC to the complementary strand of a polynucleotide which comprises one of
 CC the 5602 nucleotide sequences defined in the specification, where the
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 CC of an oligonucleotide comprising a sequence complementary to the
 CC complementary strand of a polynucleotide which comprises a 5'-end
 CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3'-end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides and the combination of
 CC the 5'-end sequence/3'-end sequence is selected from those defined in
 CC the specification. The primer sets can be used in antisense therapy and
 CC in gene therapy. The primers are useful for synthesizing polynucleotides,
 CC particularly full-length cDNAs. The primers are also useful for the
 CC detection and/or diagnosis of the abnormality of the proteins encoded by
 CC the full-length cDNAs. The primers allow obtaining of the full-length
 CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and

CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
 CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
 CC represent oligonucleotides, all of which are used in the exemplification
 CC of the present invention.
 XX Sequence 528 BP; 153 A; 89 C; 108 G; 177 T; 1 other;
 Qy 696 TTTACTCTTATGCGCATTTGCTCCATCTTCTGTGGGGGAAAAATCTAGTATTTGATT 755
 Db 518 TTACTCTTATGCGCATTTGCTCCATCTTCTGTGGGGGAAAAATCTAGTATTTGATT 460
 Qy 756 ATTTGATCTTTACGACCAAAATAGAACTCTCGCCCAATGAGAGCTTTGACCACTGAA 815
 Db 459 ATTTGATCTTTACGACCAAAATAGAACTCTCGCCCAATGAGAGCTTTGACCACTGAA 400
 Qy 816 TCACGACCGATGAGAACTCTGTCACCAAAAATGTTGGCAATAGAAATATATCAAG 875
 Db 399 TCACGACCGATGAGAACTCTGTCACCAAAAATGTTGGCAATAGAAATATATCAAG 340
 Qy 876 CAATTAATCTCCACCCCAAGGCTTCTGTAAACTGGGACCAATGATTAATGAGGCTGT 935
 Db 339 CAATTAATCTCCACCCCAAGGCTTCTGTAAACTGGGACCAATGATTAATGAGGCTGT 280
 Qy 936 TGTGAGAGATTAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 995
 Db 279 TGTGAGAGATTAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 220
 Qy 996 CATTCATGAACTTTTTCATATTAACCAAAAATTAATTAATTAATTAATTAATTAATTA 1055
 Db 219 CATTCATGAACTTTTTCATATTAACCAAAAATTAATTAATTAATTAATTAATTAATTA 160
 Qy 1056 CATCAACATGAATTTC 1072
 Db 159 CATCAACATGAATTTC 143
 RESULT 14
 AAH72087/C
 ID AAH72087 standard; cDNA; 468 BP.
 AC AAH72087;
 XX 19-SEP-2001 (first entry)
 DE Human cervical cancer marker nucleic acid 3361.
 XX Human cervical cancer; cytostatic; pre-malignant condition; gene therapy; ss.
 OS Homo sapiens.
 PN WO200142467-A2.
 PD 14-JUN-2001.
 PF 08-DEC-2000; 2000WO-US33312.
 PR 08-DEC-1999; 99US-0169681.
 PR 21-DEC-1999; 99US-0171350.
 PR 14-MAR-2000; 2000US-0189315.
 PR 12-MAY-2000; 2000US-0203791.
 PR 09-JUN-2000; 2000US-0210600.
 PR 21-JUL-2000; 2000US-0220114.
 PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 PI Schlegel R, Deeds J, Berger A, Zhao X;
 DR WPI; 2001-375006/39.

XX New isolated nucleic acid for diagnosing and treating cervical cancer
PN and for assessing and detecting compounds for treating the cancer -
XX
XX
PS Claim 1: Page 652, 1051pp; English.
XX
XX The invention relates to novel genes (AAH68727-AAH73383) associated with
CC cervical cancer with cytostatic activity. The nucleic acids and encoded
CC polypeptides are useful: to assess if a patient is afflicted with
CC cervical cancer or has a pre-malignant condition; to monitor the
CC progression of cervical cancer or a premalignant condition in a patient;
CC and to select and/or assess the efficacy of a compound or therapy for
CC inhibiting cervical cancer in a patient. The nucleic acids may also be
CC useful for gene therapy.
XX
SQ Sequence 468 BP; 131 A; 84 C; 94 G; 159 T; 0 other;

Query Match 33.2%; Score 356; DB 22; Length 468;
Best Local Similarity 100.0%; Pred. No. 7.3e-87;
Matches 356; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 717 CCATCATTTCTTGGGGGAAAAATTTCTAGATTGTTGATTGTTGATCTTACGACAA 776
DB |||||||
DB 468 CCATCATTTCTTGGGGGAAAAATTTCTAGATTGTTGATTGTTGATCTTACGACAA 409
QY 777 ATAGAACTCTGGCCAAATGAGAGCTCTTGACCAGTGAATCAGCCGATGAGACGTC 836
DB |||||||
DB 408 ATAGAACTCTGGCCAAATGAGAGCTCTTGACCAGTGAATCAGCCGATGAGACGTC 349
QY 837 TTGCCACAAAAATGTGTGGCAATATAGAGTATATCAAGCAATATCTCCACCACAA 896
DB |||||||
DB 348 TTGCCACAAAAATGTGTGGCAATATAGAGTATATCAAGCAATATCTCCACCACAA 289
QY 897 TTCTGTAAGTGGGACCATGATTACCTCATAGGCTGTTGTAGAGATTGATGAATA 956
DB |||||||
DB 288 TTCTGTAAGTGGGACCATGATTACCTCATAGGCTGTTGTAGAGATTGATGAATA 229
QY 957 CCTGTGAAGTGGCTAGGAGAGTCCAGCCAAATAGAGAGCATTCATGAACTTTTTC 1016
DB |||||||
DB 228 CCTGTGAAGTGGCTAGGAGAGTCCAGCCAAATAGAGAGCATTCATGAACTTTTTC 169
QY 1017 ATATTAACCAAAAAATTAAGTTGTTATCAATAAACTTGATCCACATGATTTTC 1072
DB |||||||
DB 168 ATATTAACCAAAAAATTAAGTTGTTATCAATAAACTTGATCCACATGATTTTC 113

RESULT 15
AAA96342
ID AAA96342 standard; cDNA; 1342 BP.
XX
XX
AC AAA96342;
XX
DT 08-FEB-2001 (first entry)
XX
DE cDNA encoding a novel polypeptide designated PRO1785.
XX
XX
KW Secreted protein: transmembrane protein; PRO1484; PRO4334; PRO1122;
KW PRO1889; PRO1890; PRO1887; PRO1785; PRO4353; PRO4357; PRO4405; PRO4356;
KW PRO4352; PRO4380; PRO4354; PRO4408; PRO5737; PRO4425; PRO5990; PRO6030;
KW PRO4424; PRO4422; PRO4430; PRO4499; tumour; obesity; diabetes;
KW insulinemia; kidney disorder; Bergers disease; nephropathy;
KW Schonelein-Henoch purpura; celiac disease; dermatitis herpetiformis;
KW Crohns disease; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 2..631
FT /tag= a
FT /transl_except= (pos: 355..357, aa: Asp)
FT sig_peptide 2..94
FT /tag= b

XX
XX MO200056889-A2.
XX
PD 28-SEP-2000.
XX
PF 01-MAR-2000; 2000MO-US05601.
XX
XX 23-MAR-1999; 99US-0125774.
XX 23-MAR-1999; 99US-0125778.
PR 24-MAR-1999; 99US-0125826.
PR 31-MAR-1999; 99US-0127035.
PR 05-APR-1999; 99US-0127706.
PR 21-APR-1999; 99US-0130359.
PR 27-APR-1999; 99US-0131270.
PR 27-APR-1999; 99US-0131272.
PR 27-APR-1999; 99US-0131291.
PR 04-MAY-1999; 99US-0132371.
PR 04-MAY-1999; 99US-0132379.
PR 04-MAY-1999; 99US-0132383.
PR 25-MAY-1999; 99US-0135750.
PR 08-JUN-1999; 99US-0138166.
PR 20-JUL-1999; 99US-0144791.
PR 03-AUG-1999; 99US-0146970.
PR 09-DEC-1999; 99US-0170262.
XX
XX (GETH) GENENTECH INC.
XX
PI Desnoyers L, Eaton DL, Goddard A, Godowski PJ, Gurney AL, Pan J;
PI Stewart TA, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2000-628263/60.
XX P-PSDB: AAB18915.
XX
PT Novel secreted and transmembrane polypeptides useful for diagnosing
PT tumour in a mammal, for identifying agonists and antagonists of the
PT polypeptide and for therapeutic use
XX
PS Claim 2; Fig 13; 222pp; English.
XX
XX The present sequence encodes a secreted or transmembrane polypeptide.
CC The specification describes polypeptides designated PRO1484, PRO4334,
CC PRO1122, PRO1889, PRO1890, PRO1887, PRO1785, PRO4353, PRO4357, PRO4405,
CC PRO4352, PRO4380, PRO4354, PRO4408, PRO5737, PRO4425, PRO5990,
CC PRO6030, PRO4424, PRO4422, PRO4430 and PRO4499. PRO1889 polypeptide is
CC useful for diagnosing tumour in a mammal. The polypeptides, their
CC agonists and antagonists are useful treating a condition associated with
CC expression or activity of the polypeptide. Conditions treated include
CC obesity, diabetes or hyper- or hypo-insulinemia. The polypeptides are
CC capable of inducing proliferation of mammalian kidney mesangial cells
CC and are therefore useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Bergers disease or other
CC nephropathies associated with Schonelein-Henoch purpura, celiac disease,
CC dermatitis herpetiformis or Crohns disease. The nucleic acids may be used
CC to generate transgenic animals for use in development and screening of
CC therapeutically useful reagents and also for chromosome identification
CC and tissue typing.
XX
SQ Sequence 1342 BP; 435 A; 242 C; 258 G; 407 T; 0 other;

Query Match 15.8%; Score 169.8; DB 21; Length 1342;
Best Local Similarity 59.0%; Pred. No. 5.6e-36;
Matches 291; Conservative 0; Mismatches 202; Indels 0; Gaps 0;

QY 97 CTCTAGACTTCAAGCGGCTCAACATCCGGGCAAACTGCTGCTGGAGAACTACCG 156
DB |||||
DB 139 ctcttagccttgaagtgaaagtgaagtgcaaaagaaagacgttctctctggaagataaa 198
QY 157 CGGATCGGTGCCCTGGTGGGAATGAGCAGAGGATGGGGCTTCACAGACGACGACTA 216
DB |||||
DB 199 aggcgaagttcactaagtgttaaacgtgccaagtgcacacacacagagaataa 258
QY 217 CCGAGCCCTGACGAGCTGACGAGACCTGGGGCCGCCACCACTTCAACGTGCTGCTT 276


```

Db      259  ctagggctgaaggaactgcacaaagagltgagccaccacttcagcgtgtgctt 318
QY      277  CCCCTGCACCACTTTGGCCACAGAGAGCCCTGACAGCAACAAGAGATTGAGACTTGC 336
Db      319  tccttgaatcaglttcgagaaatcgagagcccgcccaagcaagaaatgaatcttgc 378
QY      337  CTGCCGACCTTACAGTGTCTCATTCCTCCATGTTTAGCAAGATTGCACTCACCGGTACTGG 396
Db      379  aagaaaaactacgagtaactttcccatcttcacacaagatlaagattctagatctga 438
QY      397  TGCCCATCTGCTTCAGTACCTGCGCCAGACTTCTGGAGAGAGCCCACTGGAATT 456
Db      439  aggaagaacctgcattagatttctgttgattcttcaagaagaagaccaggttgaa 498
QY      457  CTGGAAGTACCTAGTACGCCCCAGATGGAAGAGGTGTAAGGGCTTGGGACCACTGTGTC 516
Db      499  ttggaagtaactctgtcaaccctgaggtcaagltgtgaagttctgagagccagagagcc 558
QY      517  AGTGAGAGAGGTCAAGACTCCAGATCACAGCGCTGTGAGAGAGCTCATCTACTGAACG 576
Db      559  cattgaagtcatacgccctgacatagcagctctgttagacaagtgatcataaaaaa 618
QY      577  AGAAGACTTATAA 589
Db      619  agaggaatcataga 631

```

Search completed: August 25, 2002, 06:15:39
 Job time: 3774 sec